(Q38296080)

1 September 2017

The impact of size on particulate vaccine adjuvants (English)

1 reference

1 September 2017

Ruchi R Shah

1

1 reference

1 September 2017

Derek T O'Hagan

series ordinal

2

1 reference

1 September 2017

Mansoor M Amiji

series ordinal

3

1 reference

1 September 2017

Luis A Brito

series ordinal

4

1 reference

1 September 2017

1 December 2014

1 reference

1 September 2017

1 reference

1 September 2017

9

1 reference

1 September 2017

17

1 reference

1 September 2017

2671-2681

1 reference

Biodistribution and pharmacokinetic analysis of long-circulating thiolated gelatin nanoparticles following systemic administration in breast cancer-bearing mice

1 September 2017

1 reference

https://api.crossref.org/works/10.2217%2FNNM.14.193

Biodistribution and pharmacokinetics of EGFR-targeted thiolated gelatin nanoparticles following systemic administration in pancreatic tumor-bearing mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.14.193

Poly(ethylene glycol)-modified nanocarriers for tumor-targeted and intracellular delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.14.193

Biodegradable nanoparticles for drug and gene delivery to cells and tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.14.193

Therapeutic nanoparticles for drug delivery in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.14.193

Doxil®--the first FDA-approved nano-drug: lessons learned

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.14.193

Multifunctional nanoparticles for imaging, delivery and targeting in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.14.193

Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.14.193

Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.14.193

Nanoparticles target distinct dendritic cell populations according to their size

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.14.193

Pathogen recognition and development of particulate vaccines: does size matter?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.14.193

Vaccines that facilitate antigen entry into dendritic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.14.193

Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.14.193

License to kill: Formulation requirements for optimal priming of CD8(+) CTL responses with particulate vaccine delivery systems

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.14.193

Key roles of adjuvants in modern vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.14.193

Relationship between physical and chemical properties of aluminum-containing adjuvants and immunopotentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.14.193

Vaccine adjuvants: mode of action

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.14.193

Immunology of TLR-independent vaccine adjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.14.193

Mechanism of action of clinically approved adjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.14.193

Towards an understanding of the adjuvant action of aluminium

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.14.193

Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.14.193

Role of aluminum-containing adjuvants in antigen internalization by dendritic cells in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.14.193

The history of MF59(®) adjuvant: a phoenix that arose from the ashes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.14.193

Adjuvant System AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.14.193

Enhancement of humoral response against human influenza vaccine with the simple submicron oil/water emulsion adjuvant MF59.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.14.193

Squalene and squalane emulsions as adjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.14.193

Immunogenicity and safety of MF59-adjuvanted H5N1 influenza vaccine from infancy to adolescence.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.14.193

Safety of MF59-adjuvanted influenza vaccination in the elderly: results of a comparative study of MF59-adjuvanted vaccine versus nonadjuvanted influenza vaccine in northern Italy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.14.193

Adjuvants and antibody production: dispelling the myths associated with Freund's complete and other adjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.14.193

Epaxal: a virosomal vaccine to prevent hepatitis A infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.14.193

Eleven years of Inflexal V-a virosomal adjuvanted influenza vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.14.193

Design considerations for liposomal vaccines: influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.14.193

Lipid vesicle size of an oral influenza vaccine delivery vehicle influences the Th1/Th2 bias in the immune response and protection against infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.14.193

Vesicle size influences the trafficking, processing, and presentation of antigens in lipid vesicles

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.14.193

The vesicle size of DDA:TDB liposomal adjuvants plays a role in the cell-mediated immune response but has no significant effect on antibody production.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.14.193

Cationic liposomes as vaccine adjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.14.193

Liposome-based cationic adjuvant formulations (CAF): past, present, and future

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.14.193

The long-term potential of biodegradable poly(lactide-co-glycolide) microparticles as the next-generation vaccine adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.14.193

Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.14.193

Influence of the particle size on the adjuvant effect of particulate polymeric adjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.14.193

Biodegradable particles as vaccine delivery systems: size matters

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.14.193

Relationship between the size of nanoparticles and their adjuvant activity: data from a study with an improved experimental design

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.14.193

Particle size and surface charge affect particle uptake by human dendritic cells in an in vitro model.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.14.193

Characterisation of local immune responses induced by a novel nano-particle based carrier-adjuvant in sheep.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.14.193

Size dependent immune response after subcutaneous, oral and intranasal administration of BSA loaded nanospheres.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.14.193

Novel chitosan particles and chitosan-coated emulsions inducing immune response via intranasal vaccine delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.14.193

A comparison of anionic nanoparticles and microparticles as vaccine delivery systems.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.14.193

A practical approach to the use of nanoparticles for vaccine delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.14.193

Development of a nanoparticle-based influenza vaccine using the PRINT technology.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.14.193

The adjuvant effect of MF59 is due to the oil-in-water emulsion formulation, none of the individual components induce a comparable adjuvant effect

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.14.193

Nanoparticles for drug delivery: the need for precision in reporting particle size parameters

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FNNM.14.193

21 January 2018

Identifiers

DOI

10.2217/NNM.14.193

1 reference

1 September 2017

1 reference